171 related articles for article (PubMed ID: 31538250)
41. Use of Predictive Modeling to Tailor Molecular Testing Utilization for Thyroid Nodules.
Ahmed ST; Fernandes S; Gao Q; Ow TJ; Smith RV; Schiff BA; Mehta V
Otolaryngol Head Neck Surg; 2021 Sep; 165(3):406-413. PubMed ID: 33781120
[TBL] [Abstract][Full Text] [Related]
42. Real-time elastosonography: useful tool for refining the presurgical diagnosis in thyroid nodules with indeterminate or nondiagnostic cytology.
Rago T; Scutari M; Santini F; Loiacono V; Piaggi P; Di Coscio G; Basolo F; Berti P; Pinchera A; Vitti P
J Clin Endocrinol Metab; 2010 Dec; 95(12):5274-80. PubMed ID: 20810572
[TBL] [Abstract][Full Text] [Related]
43. Utility and cost-effectiveness of molecular testing in thyroid nodules with indeterminate cytology.
Labourier E
Clin Endocrinol (Oxf); 2016 Oct; 85(4):624-31. PubMed ID: 27155136
[TBL] [Abstract][Full Text] [Related]
44. Molecular diagnosis for indeterminate thyroid nodules on fine needle aspiration: advances and limitations.
Keutgen XM; Filicori F; Fahey TJ
Expert Rev Mol Diagn; 2013 Jul; 13(6):613-23. PubMed ID: 23895130
[TBL] [Abstract][Full Text] [Related]
45. Correlation Between Histological Diagnosis and Mutational Panel Testing of Thyroid Nodules: A Two-Year Institutional Experience.
Shrestha RT; Evasovich MR; Amin K; Radulescu A; Sanghvi TS; Nelson AC; Shahi M; Burmeister LA
Thyroid; 2016 Aug; 26(8):1068-76. PubMed ID: 27283257
[TBL] [Abstract][Full Text] [Related]
46. Role of 18F-fluorodeoxyglucose positron emission tomography in preoperative assessment of cytologically indeterminate thyroid nodules.
Sebastianes FM; Cerci JJ; Zanoni PH; Soares J; Chibana LK; Tomimori EK; de Camargo RY; Izaki M; Giorgi MC; Eluf-Neto J; Meneghetti JC; Pereira MA
J Clin Endocrinol Metab; 2007 Nov; 92(11):4485-8. PubMed ID: 17684046
[TBL] [Abstract][Full Text] [Related]
47. Impact of Microcalcifications on Risk of Malignancy in Thyroid Nodules with Indeterminate or Benign Cytology.
Brophy C; Stewart J; O'Donovan N; McCarthy J; Murphy M; Sheahan P
Otolaryngol Head Neck Surg; 2016 Jan; 154(1):46-51. PubMed ID: 26392026
[TBL] [Abstract][Full Text] [Related]
48. Does frozen section have a role in the intraoperative management of thyroid nodules?
Cheng MS; Morgan JL; Serpell JW
ANZ J Surg; 2002 Aug; 72(8):570-2. PubMed ID: 12190731
[TBL] [Abstract][Full Text] [Related]
49. Galectin-3-expression analysis in the surgical selection of follicular thyroid nodules with indeterminate fine-needle aspiration cytology: a prospective multicentre study.
Bartolazzi A; Orlandi F; Saggiorato E; Volante M; Arecco F; Rossetto R; Palestini N; Ghigo E; Papotti M; Bussolati G; Martegani MP; Pantellini F; Carpi A; Giovagnoli MR; Monti S; Toscano V; Sciacchitano S; Pennelli GM; Mian C; Pelizzo MR; Rugge M; Troncone G; Palombini L; Chiappetta G; Botti G; Vecchione A; Bellocco R;
Lancet Oncol; 2008 Jun; 9(6):543-9. PubMed ID: 18495537
[TBL] [Abstract][Full Text] [Related]
50. Diagnostic accuracy of fine needle aspiration biopsy cytology and ultrasonography in patients with thyroid nodules diagnosed as benign or indeterminate before thyroidectomy.
Sugino K; Ito K; Nagahama M; Kitagawa W; Shibuya H; Ohkuwa K; Yano Y; Uruno T; Akaishi J; Suzuki A; Masaki C; Ito K
Endocr J; 2013; 60(3):375-82. PubMed ID: 23197046
[TBL] [Abstract][Full Text] [Related]
51. RAS mutations in indeterminate thyroid nodules are predictive of the follicular variant of papillary thyroid carcinoma.
An JH; Song KH; Kim SK; Park KS; Yoo YB; Yang JH; Hwang TS; Kim DL
Clin Endocrinol (Oxf); 2015 May; 82(5):760-6. PubMed ID: 25109485
[TBL] [Abstract][Full Text] [Related]
52. Significance of BRAF V600E Mutation and Cytomorphological Features for the Optimization of Papillary Thyroid Cancer Diagnostics in Cytologically Indeterminate Thyroid Nodules.
Beiša A; Kvietkauskas M; Beiša V; Stoškus M; Ostanevičiūtė E; Jasiūnas E; Griškevičius L; Šeinin D; Šileikytė A; Strupas K
Exp Clin Endocrinol Diabetes; 2019 Apr; 127(4):247-254. PubMed ID: 29566402
[TBL] [Abstract][Full Text] [Related]
53. Role of surgeon-performed ultrasound in predicting malignancy in patients with indeterminate thyroid nodules.
Méndez W; Rodgers SE; Lew JI; Montano R; Solórzano CC
Ann Surg Oncol; 2008 Sep; 15(9):2487-92. PubMed ID: 18622644
[TBL] [Abstract][Full Text] [Related]
54. Bethesda Category III, IV, and V Thyroid Nodules: Can Nodule Size Help Predict Malignancy?
Kiernan CM; Solórzano CC
J Am Coll Surg; 2017 Jul; 225(1):77-82. PubMed ID: 28223197
[TBL] [Abstract][Full Text] [Related]
55. New sonographic criteria for recommending fine-needle aspiration biopsy of nonpalpable solid nodules of the thyroid.
Kim EK; Park CS; Chung WY; Oh KK; Kim DI; Lee JT; Yoo HS
AJR Am J Roentgenol; 2002 Mar; 178(3):687-91. PubMed ID: 11856699
[TBL] [Abstract][Full Text] [Related]
56. Long- versus short-interval follow-up of cytologically benign thyroid nodules: a prospective cohort study.
Medici M; Liu X; Kwong N; Angell TE; Marqusee E; Kim MI; Alexander EK
BMC Med; 2016 Jan; 14():11. PubMed ID: 26817603
[TBL] [Abstract][Full Text] [Related]
57. Clinical diagnostic gene expression thyroid testing.
Steward DL; Kloos RT
Otolaryngol Clin North Am; 2014 Aug; 47(4):573-93. PubMed ID: 25041959
[TBL] [Abstract][Full Text] [Related]
58. Effect of malignancy rates on cost-effectiveness of routine gene expression classifier testing for indeterminate thyroid nodules.
Wu JX; Lam R; Levin M; Rao J; Sullivan PS; Yeh MW
Surgery; 2016 Jan; 159(1):118-26. PubMed ID: 26435428
[TBL] [Abstract][Full Text] [Related]
59. How to approach thyroid nodules with indeterminate cytology.
Yoon JH; Kwak JY; Kim EK; Moon HJ; Kim MJ; Kim JY; Koo HR; Kim MH
Ann Surg Oncol; 2010 Aug; 17(8):2147-55. PubMed ID: 20217250
[TBL] [Abstract][Full Text] [Related]
60. Molecular testing for indeterminate thyroid nodules: past, present, and future.
Raghunathan R; Praw SS; Livhits M
Curr Opin Endocrinol Diabetes Obes; 2023 Oct; 30(5):231-237. PubMed ID: 37530703
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
